Cost-effectiveness of CT screening in the National Lung Screening Trial.
暂无分享,去创建一个
Arash Naeim | Constantine Gatsonis | Timothy R Church | Jeremy Gorelick | Denise R Aberle | Emmett B Keeler | E. Keeler | C. Gatsonis | D. Aberle | A. Naeim | T. Church | W. Black | I. Gareen | J. Sicks | G. Silvestri | S. Soneji | J. Gorelick | William C Black | Gerard A Silvestri | JoRean D Sicks | Ilana F Gareen | Samir S Soneji
[1] Yiding Jiang,et al. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. , 2012, Health affairs.
[2] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[3] A A Stinnett. Adjusting for bias in C/E ratio estimates. , 1996, Health economics.
[4] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[5] H. Sox. Better evidence about screening for lung cancer. , 2011, The New England journal of medicine.
[6] E. Arias. United States life tables, 2009. , 2014, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[7] C. Earle,et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. , 2000, Lung cancer.
[8] J. Gohagan,et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. , 2011, JAMA.
[9] H. D. de Koning,et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON) , 2009, British Journal of Cancer.
[10] C. Henschke,et al. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. , 2003, Chest.
[11] H. Welch,et al. Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.
[12] B. Kramer,et al. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology , 2013, Cancer.
[13] D. Berry,et al. Benefits and harms of CT screening for lung cancer: a systematic review. , 2012, JAMA.
[14] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[15] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[16] M. Roizen. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[17] D. Aberle,et al. Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.
[18] I. Gareen,et al. Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: the model used by the American College of Radiology arm of the National Lung Screening Trial. , 2013, Contemporary clinical trials.
[19] H. D. de Koning,et al. The impact of a lung cancer computed tomography screening result on smoking abstinence , 2010, European Respiratory Journal.
[20] M. Mcgrath. Cost Effectiveness in Health and Medicine. , 1998 .
[21] Colleen Bouzan,et al. Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] Timothy R Church,et al. Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.
[23] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[24] James Waterman Glover. United States Life Tables , 2013 .
[25] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] Milton C. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996 .
[27] E. Pisano,et al. Consequences of false-positive screening mammograms. , 2014, JAMA internal medicine.
[28] Massimo Bellomi,et al. Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer , 2012, Annals of Internal Medicine.
[29] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[30] William Hazelton,et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.
[31] John Eng,et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. , 2003, JAMA.
[32] C. Gatsonis,et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial , 2014, Cancer.
[33] O. Miettinen,et al. Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .
[34] V. Moyer. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.
[35] Andrew Dalton,et al. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. , 2005, Lung cancer.
[36] D. Lynch,et al. The National Lung Screening Trial: overview and study design. , 2011, Radiology.
[37] C. Berg,et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. , 2013, The New England journal of medicine.